Reports Q1 revenue $32.704M, consensus $40.16M. “Following compelling topline results from our pivotal Phase 3 trial of setmelanotide in acquired hypothalamic obesity (HO), we look forward to completing U.S. and EU regulatory submissions in the third quarter of 2025 and, pending approval, bringing the first-ever known approved therapy for this serious disease to patients,” said David Meeker, M.D., Chairman, Chief Executive Officer and President of Rhythm. “In addition, we are advancing our next-generation MC4R agonists as we are on track to read out topline data from the Phase 2 trial evaluating the oral-daily bivamelagon in patients with HO in the third quarter of 2025.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Promising Outlook for Rhythm Pharmaceuticals: Buy Rating Backed by Positive Phase 3 Results and Market Expansion Plans
- Rhythm Pharmaceuticals Stock (RYTM) Surges 18% Following Positive Clinical Trial Results
- Biotech Alert: Searches spiking for these stocks today
- Buy Rating Affirmed for Rhythm Pharmaceuticals: Promising Phase 3 Results for Setmelanotide in Obesity Treatment
- Rhythm Pharmaceuticals price target raised to $68 from $63 at BofA